Financials in USD. Standardized financial statements.
A compact view of how Winston Pharmaceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2009 | FY 2008 | FY 2007 | FY 2006 | FY 2005 |
|---|---|---|---|---|---|
| Revenue? | $1.39M | $452,542 | $0 | $0 | $0 |
| Revenue Growth? | +208.2% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $9,007 | $8,651 | $0 | $208,949 | $19,849 |
| Gross Profit? | $1.39M | $443,891 | $0 | -$208,949 | -$19,849 |
| Gross Margin? | +99.4% | +98.1% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $4.13M | $5.68M | $214,982 | $216,696 | $198,061 |
| Operating Income? | -$2.74M | -$5.23M | -$214,982 | -$425,645 | -$217,910 |
| EBITDA? | -$2.73M | -$5.23M | -$199,982 | -$418,469 | -$207,588 |
| Income Before Tax | -$2.66M | -$5.14M | $0 | $0 | $0 |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$2.66M | -$5.14M | -$180,105 | -$464,995 | -$230,800 |
| EPS? | $-0.04 | $-0.10 | $-0.08 | $-0.80 | $-0.40 |
| Diluted EPS? | $-0.04 | $-0.10 | $-0.08 | $-0.80 | $-0.40 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality